Literature DB >> 22354323

CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma.

Yong Shi1, Hong-Li Gong, Liang Zhou, Jie Tian, Yang Wang.   

Abstract

PURPOSE: To investigate the role of CD24 in tumor invasion and the clinical significance of its expression in laryngeal squamous cell carcinoma (LSCC). PROCEDURES: CD24 expression was measured in Hep-2 cell lines and tumor and peritumoral tissues by quantitative real-time PCR and Western blot analysis. The role of CD24 in LSCC was investigated by CD24 depletion using small interfering RNA. Tumor tissue microarrays with samples from 102 LSCC patients were used to detect expression of CD24 and proliferating cell nuclear antigen (PCNA). Prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests.
RESULTS: CD24 was overexpressed in the LSCC cell line and in tumor tissues. Depletion of CD24 caused a notable decrease in cell proliferation, migration and invasiveness in vitro. High CD24 expression was significantly associated with T clinic stage, lymph node metastasis and tumor size (p < 0.05). Patients suffering from LSCC recurrence had higher levels of CD24 protein than those without recurrence (p < 0.0001). The proportion of patients with high PCNA expression was significantly greater among patients with CD24+ LSCC than those with CD24- LSCC (p = 0.000). Univariate and multivariate analyses revealed that CD24 was a significant predictor for overall survival.
CONCLUSIONS: Overexpression of CD24 in LSCC is associated with invasiveness, metastatic potential and high tumor proliferation status. CD24 may be a promising strategy for the future treatment of LSCC metastasis and recurrence.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354323     DOI: 10.1159/000335584

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  11 in total

1.  Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma.

Authors:  J Tang; H Cai; L Lin; P Xie; W Zhong; M Tang
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

2.  Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.

Authors:  Haofei Wang; Wujun Wang; Xuelian Wang; Kaican Cai; Hua Wu; Qun Ju; Zhiyong Huang; Xuhui Gao
Journal:  Med Oncol       Date:  2012-04-22       Impact factor: 3.064

3.  Prognostic utility of SOX2, STAT3, and CD44high/CD24low expression in penile cancer.

Authors:  Felipe Dubourcq de Barros; Leuridan Cavalcante Torres; Carolline Araujo; Felipe da Silva Marinho; Beatriz Cavalcanti Dubourcq; Luís Cavalcanti Dubourcq; Gustavo Cardoso Guimarães
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-01       Impact factor: 4.322

4.  Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma.

Authors:  Yuan Mao; Da-Wei Zhang; Hong Lin; Lin Xiong; Ying Liu; Qing-Dong Li; Jun Ma; Qing Cao; Ren-Jie Chen; Jin Zhu; Zhen-Qing Feng
Journal:  J Exp Clin Cancer Res       Date:  2012-12-12

5.  CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer.

Authors:  Tomohito Tanaka; Yoshito Terai; Yuhei Kogata; Keisuke Ashihara; Kazuya Maeda; Satoe Fujiwara; Saha Yoo; Yoshimichi Tanaka; Satoshi Tsunetoh; Hiroshi Sasaki; Masanori Kanemura; Akiko Tanabe; Masahide Ohmichi
Journal:  Oncol Rep       Date:  2015-09-08       Impact factor: 3.906

6.  CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2.

Authors:  Kawin Leelawat; Siriporn Keeratichamroen; Surang Leelawat; Rutaiwan Tohtong
Journal:  Oncol Lett       Date:  2013-09-17       Impact factor: 2.967

7.  CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma.

Authors:  Vishnu Modur; Pooja Joshi; Daotai Nie; K Thomas Robbins; Aziz U Khan; Krishna Rao
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

8.  Downregulation of CD24 suppresses bone metastasis of lung cancer.

Authors:  Hinako Okabe; Katsuhiko Aoki; Satomi Yogosawa; Mitsuru Saito; Keishi Marumo; Kiyotsugu Yoshida
Journal:  Cancer Sci       Date:  2017-11-29       Impact factor: 6.716

9.  CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.

Authors:  Kiyoko Nakamura; Yoshito Terai; Akiko Tanabe; Yoshihiro J Ono; Masami Hayashi; Kazuya Maeda; Satoe Fujiwara; Keisuke Ashihara; Michihiko Nakamura; Yoshimichi Tanaka; Tomohito Tanaka; Satoshi Tsunetoh; Hiroshi Sasaki; Masahide Ohmichi
Journal:  Oncol Rep       Date:  2017-04-19       Impact factor: 3.906

10.  EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells.

Authors:  Jiameng Huang; Liang Zhou; Hui Chen; Chunping Wu; Zhang Duo; Yanping Zhang
Journal:  Oncol Lett       Date:  2016-06-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.